You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Talimogene laherparepvec for treating unresectable metastatic melanoma

  • Technology appraisal guidance
  • Reference number: TA410
  • Published:  28 September 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 Evidence
  • 4 Committee discussion
  • 5 Implementation
  • 6 Appraisal committee members and NICE project team
  • Update information

3 Evidence

The appraisal committee considered evidence submitted by Amgen and a review of this submission by the evidence review group (ERG). It also considered evidence received from patient and professional groups. See the committee papers for full details of the evidence.


Next page 4 Committee discussion Previous page 2 The technology
Back to top